ArticleProceedings of the National Academy of Sciences of the United States of America2019
Retinal and optic nerve degeneration in liver X receptor β knockout mice.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 26 citations in OpenAlex.
- LXR Pathway Activation by T0901317: A Novel Potential Experimental Strategy for ALS-Related Cognitive and Motor Impairments via Suppression of Necroptosis-associated RIPK1/RIPK3/MLKL Markers.Molecular neurobiology · 2026Article
- Role of LXRβ in oligodendrocytes in neuronal survival.Molecular psychiatry · 2026Article
- Regulated Necrosis in Glaucoma: Focus on Ferroptosis and Pyroptosis.Molecular neurobiology · 2024Review
- Loss of ERβ in Aging LXRαβ Knockout Mice Leads to Colitis.International journal of molecular sciences · 2023Article
- Miconazole Promotes Cooperative Ability of a Mouse Model of Alzheimer Disease.The international journal of neuropsychopharmacology · 2022Article
- Liver X Receptor Regulation of Glial Cell Functions in the CNS.Biomedicines · 2022Review
- Article
- Liver fibrosis and retinal features in an older Mediterranean population: Results from the Salus in Apulia study.Frontiers in neuroscience · 2022Article
- Review
- Role of Retinal Amyloid-β in Neurodegenerative Diseases: Overlapping Mechanisms and Emerging Clinical Applications.International journal of molecular sciences · 2021Review
- Selective LXR agonist DMHCA corrects retinal and bone marrow dysfunction in type 2 diabetes.JCI insight · 2020Article
- Leveraging Nuclear Receptors as Targets for Pathological Ocular Vascular Diseases.International journal of molecular sciences · 2020Review
- LXRs regulate features of age-related macular degeneration and may be a potential therapeutic target.JCI insight · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The retina is an extension of the brain. Like the brain, neurodegeneration of the retina occurs with age and is the cause of several retinal diseases including optic neuritis, macular degeneration, and glaucoma. Liver X receptors (LXRs) are expressed in the brain where they play a key role in maintenance of cerebrospinal fluid and the health of dopaminergic neurons. Herein, we report that LXRs are expressed in the retina and optic nerve and that loss of LXRβ, but not LXRα, leads to loss of ganglion cells in the retina. In the retina of LXRβ
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.